slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 40,051-40,080
Pages 2,019
Rows per page 30
Component
40,051-40,080 of 60,568
29
The slide provides a detailed breakdown of adjustments made to GAAP operating income to arrive at non-GAAP Adjusted EBITA for two consecutive first quarters.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations 1 hit
30
Includes two separate tables: one for consolidated EBITDA reconciliation and one for noncontrolling interest adjustments.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations 1 hit
31
The table provides a detailed breakdown of revenue adjustments including exchange rates, acquisitions, and divestitures.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations 1 hit
32
In millions USDBausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations 1 hit
33
The table reconciles GAAP operating cash flow to a non-GAAP adjusted figure by adding back specific costs like legal settlements, transformation costs, and separation costs.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations 1 hit
34
The table provides a detailed breakdown of adjustments including impairments, restructuring costs, and share-based compensation to arrive at non-GAAP Adjusted EBITDA.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations 1 hit
35
The slide provides a detailed breakdown of adjustments including asset impairments, restructuring costs, and share-based compensation.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations 1 hit
13
Includes adjustments for open mark-to-market timing differences and excludes Fresh Business.Benson Hill | Results Presentation Deck | 23 slides · Benson Hill
Conference presentation Investor relations Beat · Desire1 hit
14
The table highlights the impact of a Liquidity Improvement Plan on OPEX, EBITDA, and Free Cash Flow.Benson Hill | Results Presentation Deck | 23 slides · Benson Hill
Conference presentation Investor relations Beat · Desire1 hit
18
USD in thousands, except per share information.Benson Hill | Results Presentation Deck | 23 slides · Benson Hill
Conference presentation Investor relations 1 hit
20
Benson Hill financial disclosure.Benson Hill | Results Presentation Deck | 23 slides · Benson Hill
Conference presentation Investor relations 1 hit
21
The table reconciles reported figures to adjusted figures by removing mark-to-market timing impacts.Benson Hill | Results Presentation Deck | 23 slides · Benson Hill
Conference presentation Investor relations 1 hit
23
Includes a footnote regarding the exclusion of the Fresh business.Benson Hill | Results Presentation Deck | 23 slides · Benson Hill
Conference presentation Investor relations 1 hit
14
Includes QTD Q4 2022, YTD Q4 2022, and Forecasted QTD Q2 2023 data.Berkeley Lights | Investor Presentation Deck | 15 slides · PhenomeX
Pitch deck Investor relations Beat · Financials1 hit
08
The slide uses a Gantt-style visualization to represent clinical trial phases for multiple drug candidates.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
21
Includes specific clinical trial safety metrics and footnotes regarding data definitions.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
23
The table details specific drug administration schedules (mg/kg) on days 1, 8, 15, and 22 for different cycle lengths.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
24
Includes abbreviations for LMS, UPS, and NSCLC at the bottom.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
31
The slide presents clinical data points (PR/CR rates) to justify moving to Phase 2.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
33
The table details specific drug administration schedules (mg/kg) for different cycle lengths and days.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
34
The table lists specific indications (NSCLC, Melanoma, Head and Neck, Ovarian) and their corresponding dosing schedules (Q2W, 3Q4W) and patient counts (N ~ 20 or 40).BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
36
The slide uses a combination of a summary table for clinical data and a dot plot for NHP toxicity data.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
39
The slide uses a before-after framing (problem vs solution) and presents preclinical data (tumor shrinkage and toxicity studies).BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
41
The slide uses a table structure to represent a timeline of events.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Loop · Why Now1 hit
19
Blue Apron | Results Presentation Deck | 21 slidesBlue Apron | Results Presentation Deck | 21 slides · Blue Apron
Conference presentation Investor relations 1 hit
20
Blue Apron | Results Presentation Deck | 21 slidesBlue Apron | Results Presentation Deck | 21 slides · Blue Apron
Conference presentation Investor relations 1 hit
23
The table includes a footnote regarding the adoption of ASC 842.Blue Apron | Results Presentation Deck | 24 slides · Blue Apron
Conference presentation Investor relations 1 hit
16
The slide uses a combination of a bar chart and a supporting data table to demonstrate the 'J-curve' of medical center profitability.Cano Health | Investor Presentation Deck | 48 slides · Cano Health
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
32
This is a classic 'Before/After' or 'Claim/Fact' framing used in proxy contests.Cano Health | Investor Presentation Deck | 48 slides · Cano Health
Pitch deck Investor relations 1 hit
39
Includes specific financial metrics like MCR, Adjusted EBITDA, and additional expense guidance.Cano Health | Investor Presentation Deck | 48 slides · Cano Health
Pitch deck Investor relations 1 hit